Paratek Pharmaceuticals Inc. (PRTK) announced after the close Monday that its Phase 3 study of omadacycline in patients with acute bacterial skin and skin structure infections met all of its primary and secondary endpoints. The stock is now up 0.94 on 270K shares.
from RTT - Before the Bell http://ift.tt/2tzdzJJ
via IFTTT
No comments:
Post a Comment